...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of dermatology >Treatment for taxane‐resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases
【24h】

Treatment for taxane‐resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases

机译：Treatment for taxane‐resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

Abstract Cutaneous angiosarcoma (CAS) is a rare and highly aggressive type of vascular tumor. Although chemoradiotherapy with taxanes is recognized as a first‐line therapy for CAS, second‐line therapy for CAS remains controversial. From the above findings, the efficacy and safety profiles of taxane‐switch (change paclitaxel to docetaxel or vise), eribulin methylate, and pazopanib regimens in second‐line chemotherapy were evaluated retrospectively in 50 Japanese taxane‐resistant CAS patients. Although there was no significant difference in progression‐free survival (P?=?0.3528) among the regimens, the incidence of all adverse events (AEs) (P?=?0.0386), as well as severe G3 or more AEs (P?=?0.0477) was significantly higher in the eribulin methylate group and pazopanib group than in the taxane‐switch group. The present data suggest that switching to another taxane should be considered for the treatment of taxane‐resistant CAS in second‐line therapy based on the safety profiles.

著录项

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号